Control of hypereosinophilic syndrome-associated recalcitrant coronary artery spasm by combined treatment with prednisone, imatinib mesylate and hydroxyurea

Experimental and Clinical Cardiology

Volumn 11, Issue 1, 2006, Pages 25-28

  Butterfield, Joseph H ^a   Sharkey, Scott W ^b  

^a MAYO CLINIC   (United States)

^b MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

Author keywords

Coronary artery spasm; Hydroxyurea; Idiopathic hypereosinophilic syndrome; Imatinib mesylate

Indexed keywords

ALPHA2B INTERFERON; ARGININE; CALCIUM CHANNEL BLOCKING AGENT; GLYCERYL TRINITRATE; HYDROXYUREA; IMATINIB; MORPHINE SULFATE; NITRIC ACID DERIVATIVE; PREDNISONE; RAMIPRIL; SILDENAFIL; STATIN; TRYPTASE;

ADULT; ANAMNESIS; ANGIOCARDIOGRAPHY; ARTICLE; BONE MARROW BIOPSY; BRONCHOSCOPY; CARDIOVERSION; CASE REPORT; CLINICAL FEATURE; CORONARY ARTERY SPASM; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; EOSINOPHIL COUNT; FEMALE; GENE DELETION; HEART ARREST; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICULOGRAPHY; HUMAN; HYPEREOSINOPHILIC SYNDROME; LABORATORY TEST; LUNG BIOPSY; MAINTENANCE DRUG DOSE; MASTOCYTOSIS; RECURRENT DISEASE; ST SEGMENT ELEVATION; THORAX PAIN; TREATMENT RESPONSE;

EID: 33744479743     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Hirakawa Y, Koyanagi S, Matsumoto T, Takeshita A, Nakamura M. A case of variant angina associated with eosinophilia. Am J Med 1989;87:472-4.
2. Horigome H, Sekijima T, Ohtsuka S, Shibasaki M. Life threatening coronary artery spasm in childhood Kimura's disease. Heart 2000;84:E5.
3. Hertzman PA, Maddoux GL, Sternberg EM, et al. Repeated coronary artery spasm in a young woman with the eosinophilia-myalgia syndrome. JAMA 1992;267:2932-4.
4. Getz MA, Subramanian R, Logemann T, Ballantyne F. Acute necrotizing eosinophilic myocarditis as a manifestation of severe hypersensitivity myocarditis. Antemortem diagnosis and successful treatment. Ann Intern Med 1991;115:201-2.
5. Frustaci A, Abdulla AK, Possati G, Manzoli U. Persisting hypereosinophilia and myocardial activity in the fibrotic stage of endomyocardial disease. Chest 1989;96:674-5.
6. Davies J, Spry CJ, Sapsford R, et al. Cardiovascular features of 11 patients with eosinophilic endomyocardial disease. Q J Med 1983;52:23-39.
7. Pitt M, Davies MK, Brady AJ. Hypereosinophilic syndrome: Endomyocardial fibrosis. Heart 1996;76:377-8.
8. Parrillo JE, Borer JS, Henry WL, Wolff SM, Fauci AS. The cardiovascular manifestations of the hypereosinophilic syndrome. Prospective study of 26 patients, with review of the literature. Am J Med 1979;67:572-82.
9. Sekiguchi M, Yu ZX, Take M, et al. Ultrastructural features of the endomyocardium in patients with eosinophilic heart disease. An endomyocardial biopsy study. Jpn Circ J 1984;48:1375-82.
10. Tai PC, Spry CJ. The mechanisms which produce vacuolated and degranulated eosinophils. Br J Haematol 1981;49:219-26.
11. Spry CJ, Tai PC. Studies on blood eosinophils. II. Patients with Loffler's cardiomyopathy. Clin Exp Immunol 1976;24:423-34.
12. Davies J, Sapsford R, Brooksby I, et al. Successful surgical treatment of two patients with eosinophilic endomyocardial disease. Br Heart J 1981;46:438-45.
13. Arvay A, Lengyel M, Meszaros R, Palik I. Surgical experience with thrombotic and fibrotic forms of non-tropical eosinophilic endomyocardial disease. Thorac Cardiovasc Surg 1985;33:314-6.
14. Cameron J, Radford DJ, Howell J, O'Brien MF. Hypereosinophilic heart disease. Med J Aust 1985;143:408-10.
15. Wood AE, Boyle D, O'Hara MD, Cleland J. Mitral annuloplasty in endomyocardial fibrosis: An alternative to valve replacement. Ann Thorac Surg 1982;34:446-51.
16. Cohen J, Davies J, Goodwin JF, Spry CJ. Arrhythmias in patients with hypereosinophilia: A comparison of patients with and without Loffler's endomyocardial disease. Postgrad Med J 1980;56:828-32.
17. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-14.
18. Hardy WR, Anderson RE. The hypereosinophilic syndromes. Ann Intern Med 1968;68:1220-9.
19. Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003;102:3093-6.
20. Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: Prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004;104:3038-45.
21. Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003;101:4660-6.
22. Spry CJ, Take M, Tai PC. Eosinophilic disorders affecting the myocardium and endocardium: A review. Heart Vessels Suppl 1985;1:240-2.
23. Molina HA, Kierszenbaum F. Immunohistochemical detection of deposits of eosinophil-derived neurotoxin and eosinophil peroxidase in the myocardium of patients with Chagas' disease. Immunology 1988;64:725-31.
24. Tai PC, Ackerman SJ, Spry CJ, Dunnette S, Olsen EG, Gleich GJ. Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease. Lancet 1987;1:643-7.
25. Kishimoto C, Spry CJ, Tai PC, Tomioka N, Kawai C. The in vivo cardiotoxic effect of eosinophilic cationic protein in an animal preparation. Jpn Circ J 1986;50:1264-7.
26. Tai PC, Hayes DJ, Clark JB, Spry CJ. Toxic effects of human eosinophil products on isolated rate heart cells in vitro. Biochem J 1982;204:75-80.
27. Desreumaux P, Janin A, Dubucquoi S, et al. Synthesis of interleukin-5 by activated eosinophils in patients with eosinophilic heart diseases. Blood 1993;82:1553-60.
28. Mukai HY, Ninomiya H, Ohtani K, Nagasawa T, Abe T. Major basic protein binding to thrombomodulin potentially contributes to the thrombosis in patients with eosinophilia. Br J Haematol 1995;90:892-9.
29. Venge P, Dahl R, Hallgren R. Enhancement of factor XII dependent reactions by eosinophil cationic protein. Thromb Res 1979;14:641-9.
30. Rohrbach MS, Wheatley CL, Slifman NR, Gleich GJ. Activation of platelets by eosinophil granule proteins. J Exp Med 1990;172:1271-4.
31. Slungaard A, Vercellotti GM, Tran T, Gleich GJ, Key NS. Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease. J Clin Invest 1993;91:1721-30.
32. Pardanani A, Reeder T, Porrata LF, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003;101:3391-7.
33. van den Anker-Lugtenburg PJ, van't Veer MB. Alpha-interferon in a case of hypereosinophilic syndrome. Br J Haematol 1991;77:258.
34. Bokenstedt PL, Santinga JT, Bolling SF. Alpha-interferon treatment for idiopathic hypereosinophilic syndrome. Am J Hematol 1994;45:248-51.
35. Forman MB, Oates JA, Robertson D, Robertson RM, Roberts LJ II, Virmani R. Increased adventitial mast cells in a patient with coronary spasm. N Engl J Med 1985;313:1138-41.
36. Zielinski RM, Lawrence WD. Interferon-alpha for the hypereosinophilic syndrome. Ann Intern Med 1990;113:716-8.
37. Yoon TY, Ahn GB, Chang SH. Complete remission of hypereosinophilic syndrome after interferon-alpha therapy: Report of a case and literature review. J Dermatol 2000;27:110-5.
38. Butterfield JH, Gleich GJ. Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann Intern Med 1994;121:648-53.